News & Announcements

Featured Story

Latest from Aveiaa

Company Launch

Aveiaa AI Officially Launches Its Causal Intelligence Platform for Drug Development

Aveiaa AI announces the official launch of its scientific intelligence platform — a first-of-its-kind system that integrates causal reasoning, pharmaceutical science, and regulatory intelligence to transform how drug development decisions are made. The platform is now available for early access partnerships with pharmaceutical companies, research institutions, and biotech innovators.

Get Early Access June 2026

What's Happening

Product

CMDNS™ v1.0 Released — Causal Molecular Drug Navigation Now Available

Aveiaa's flagship causal reasoning engine, CMDNS™, is now available for integration. The system encodes mechanistic relationships from molecular structure to clinical outcome, enabling teams to model why drugs behave the way they do.

May 2026 Learn More →

Partnership

Aveiaa Partners with adtech to Lead Platform Engineering & Enterprise Delivery

Aveiaa has formalized its founding technology partnership with adtech, bringing together senior enterprise technology leadership, AI engineering, and platform architecture expertise to accelerate the platform's development and go-to-market execution.

April 2026 Learn More →

Research

Knowledge Intelligence Vault™ Integrates Validated Pharmaceutical Evidence Networks

The Knowledge Intelligence Vault™ now incorporates structured evidence networks from peer-reviewed literature, regulatory submissions, and proprietary data sources — enabling context-aware reasoning across drug discovery and development workflows.

March 2026 Learn More →

Product

BioIntelligence™ Module Launches for Model-Informed Bioequivalence Studies

Aveiaa's BioIntelligence™ module is now in early access, offering model-informed bioequivalence intelligence designed to enrich missing data, identify risk drivers, and guide next actions in generic drug development programs.

February 2026 Learn More →

Team

Aveiaa Expands Scientific Advisory Board with Dr. Ashraf Qasem from University of Bath

Dr. Ashraf M. A. Qasem, a pharmaceutical scientist specializing in natural product-derived therapeutics and NMR-based structural elucidation, joins Aveiaa's Scientific Advisory Board to strengthen the platform's drug discovery and translational research foundation.

January 2026 Meet the Team →

Insight

Why Causal AI Is the Missing Layer in Pharmaceutical R&D Decision-Making

Aveiaa's founding team publishes a perspective piece on why current AI tools in pharma remain correlation-driven — and how causal graph-based systems represent the next essential layer of intelligence for R&D teams navigating complex development decisions.

December 2025 Read Publication →

Company Updates

Official Announcements

Key milestones, operational updates, and strategic developments directly from the Aveiaa team.

Get in Touch

Launch

Aveiaa AI Platform — Early Access Now Open

We are accepting a limited number of early access partners across pharmaceutical R&D, biotech, and academic research. Early partners receive dedicated onboarding, custom integration support, and founding partner pricing.

June 2026

Team

Leadership Team Finalized — Six-Person Founding Team Now Complete

Aveiaa's founding team is now complete, combining expertise across pharmaceutical science, AI engineering, enterprise technology, drug discovery, and translational research to drive the platform's development and go-to-market strategy.

May 2026

Operations

Aveiaa Establishes Headquarters in Amman, Jordan

Aveiaa AI has established its primary operations in Amman, Jordan, positioning itself at the intersection of regional pharmaceutical growth and global AI innovation. The company is actively building partnerships across the MENA region and internationally.

April 2026

Publications

First Scientific Publication on Causal Drug Development Intelligence Submitted

Aveiaa's scientific team has submitted its first peer-reviewed publication outlining the theoretical and architectural foundations of causal intelligence in pharmaceutical R&D. The paper is currently under review.

March 2026